UBS raises Teladoc stock price target on margin improvement
UBS raised its price target for Teladoc Health (NYSE:TDOC) to $9.00 from $6.50, citing margin improvements. The stock trades at $8.51, with a Fair Value of $11.80 according to InvestingPro. UBS maintained a Neutral rating due to competitive pressures. Teladoc's Q3 2026 results beat expectations, with revenue of $605.1 million and a smaller loss per share. The company raised its full-year revenue and EBITDA guidance.
How this was made
The 30-second read
Why it matters
The earnings beat and higher target could attract short‑term buying, but competitive pressures remain.
Market read
The news provides a fresh catalyst for TDOC, potentially influencing its near‑term price action.
What to watch
Potential headwinds from competitive pricing and macro‑economic slowdown.
Background
Analyst UBS updates its valuation model for Teladoc Health after the company posted Q3 2026 results that beat expectations.
Ticker impact
UBS raised its price target on Teladoc Health to $9.00 and reported better‑than‑expected Q3 2026 earnings, indicating margin improvement.
likely modest upside as the market prices in improved margins and higher target
The combination of a fresh earnings beat and a higher price target provides a concrete, time‑sensitive catalyst.
Market effects
Positive margin trends may lift other digital‑health peers.
U.S. healthcare sector sees modest support.
Limited to U.S. and global telehealth investors.
Counterpoint
Target raise may be premature if BetterHelp insurance growth stalls.
Key entities
- companyTeladoc Health Inc.
U.S. telehealth provider reporting Q3 2026 earnings.
- analyst_firmUBS
Raised price target to $9.00 from $6.50.
